FDA and FTC warned CBD seller Nature's Highway for selling unapproved drugs claimed to treat or prevent COVID-19.
What happened
FDA reviewed the company's website on February 17, 2022, and the FTC reviewed it on March 7, 2022; both also looked at a linked Facebook page that sends buyers to the site. The letter says the sites offer hemp-derived CBD products with statements that CBD may help treat, prevent, or ease COVID-19, which makes the products unapproved new drugs and misbranded. No manufacturing inspection took place.
What FDA found
The company sells CBD products as drugs for COVID-19 without FDA approval.
Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The product labels and websites lack the information the law requires for drugs, so the products are misbranded.
Section 502 of the FD&C Act, 21 U.S.C. § 352Shipping these unapproved and misbranded products across state lines is prohibited.
Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)The company advertises that its products prevent, treat, or cure disease without solid scientific evidence to back the claims.
FTC Act, 15 U.S.C. § 41 et seq.Deceptive claims about treating, curing, preventing, or easing COVID-19 can bring civil penalties of up to $46,517 per violation.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA asks the company to stop selling the unapproved COVID-19 products immediately and, within 48 hours, email a description of the corrective steps taken and how it will prevent repeat violations. The FTC separately asks for an email within 48 hours certifying that the unsupported claims have stopped.
Who should pay attention
- CBD and supplement brands making health claims on their websites
- online sellers marketing products against COVID-19
- retailers and marketplaces carrying hemp-derived CBD products
This is a summary. Read the original letter on fda.gov.